

# Russian Pharma Sector Forecast to 2013

<https://marketpublishers.com/r/RDB40478C51EN.html>

Date: March 2011

Pages: 100

Price: US\$ 800.00 (Single User License)

ID: RDB40478C51EN

## Abstracts

**Single User PDF Format:** US\$ 800.00

**Multi-User License:** US\$ 1,200.00

**Hard Copy:** US\$ 900.00

**CD-ROM:** US\$ 900.00

The Russian pharma industry is one of the most prolific sectors in the healthcare industry, showing an unprecedented growth of over 17% to generate revenue worth about RUB 538 Billion (US\$ 16.14 Billion) in 2009. This high growth rate can be attributed to the development incentives announced by the government for the state drugs segment. The government is also taking the required steps to boost the domestic pharma industry and reduce the dependence on imported products. The Para-pharmaceuticals segment has become one of the leading segments, which has been benefited from the strong young population demand.

According to our new research report "Russian Pharma Sector Forecast to 2013", the Russian pharma sector is projected to show double-digit growth in near future owing to a rise in investments by the private sector, most importantly the foreign players. Besides, to cater to a large percentage of the population, pharma companies are now shifting their focus towards the research and development projects for manufacturing generic drugs that are less expensive. To understand the direction of the industry, we have done an extensive research and analysis of various segments of the pharma market in the Russian Federation. These segments include: Commercial Drug Segment, State Segment, and the Para-pharmaceutical Segment.

Growth of the Russian pharmaceutical industry is based on the rising health conscious and consequent rise in the healthcare expenditure of the population. Additionally, rising prevalence of diseases and demand for cheaper drugs will be some of the other important drivers for future growth. The overall improvement in the healthcare industry will also pave way for the Russian pharma market to continue its upward trend during

the forecast period (2011-2013).

The report provides precise and reliable information, supplemented with statistics, regarding the Russian pharma sector. The report covers leading drugs, segment-wise break up, and information about major therapy areas. It has thoroughly examined current market trends; industrial developments, and competitive landscape to enable clients understand the market structure and its progress in coming years. Forecasts have been done considering the possible impact of recession on the industry.

The report also presents a brief overview of demographics and healthcare profile to adjudge the pharmaceutical market in terms of demands, expenditure, and possible future direction.

## Contents

### **1. ANALYST VIEW**

### **2. DEMOGRAPHICS & HEALTHCARE PROFILE**

- 2.1 Life Expectancy
- 2.2 Age Breakup
- 2.3 Hospital Beds & Doctors
- 2.4 Healthcare Expenditure

### **3. PHARMACEUTICAL MARKET FORECAST TO 2013**

- 3.1 Market Size & Growth
- 3.2 Comparative Analysis
- 3.3 Market Segmentation by Expenditure
- 3.4 Commercial Drugs Market
  - 3.4.1 Imported & Domestic Drugs
  - 3.4.2 RX & OTC Drugs
  - 3.4.3 Sales Structure - By ATC Groups
  - 3.4.4 Leading Companies
  - 3.4.5 Leading Drugs
  - 3.4.6 Price Analysis
- 3.5 State Segment
  - 3.5.1 Drug Reimbursement Program (DLO)
    - 3.5.1.1 Imported & Domestic Drugs
    - 3.5.1.2 RX & OTC Drugs
    - 3.5.1.3 Sales Structure - By ATC Groups
    - 3.5.1.4 Leading Companies
    - 3.5.1.5 Leading Drugs
  - 3.5.2 Hospital Segment
    - 3.5.2.1 Imported & Domestic Drugs
    - 3.5.2.2 Sales Structure - By ATC Groups
    - 3.5.2.3 Leading Companies
    - 3.5.2.4 Leading Drugs
- 3.6 Parapharmaceutical Market
  - 3.6.1 Nutritional Supplements Market
    - 3.6.1.1 Imported & Domestic Supplements
- 3.7 Market by Disease Segment

- 3.7.1 Cardiovascular Drugs
- 3.7.2 Hepatitis C
- 3.7.3 HIV Drugs
- 3.7.4 High Insulin Demand
- 3.7.5 Cancer Drugs

## **4. CLINICAL TRIALS MARKET OUTLOOK**

## **5. INDUSTRY ANALYSIS**

- 5.1 Market Driving Forces
  - 5.1.1 Increasing Volume & Sales of Expensive Drugs
  - 5.1.2 Rising Expenditure on Infrastructure Development
  - 5.1.3 Increasing Acceptance of the Contract Manufacturing Model
  - 5.1.4 Rising Healthcare Coverage Improving Drug Affordability
- 5.2 Market Roadblocks
  - 5.2.1 Declining Population
  - 5.2.2 Drug Counterfeiting & Weak IPR Regime

## **6. REGULATORY ENVIRONMENT**

## **7. COMPETITIVE ANALYSIS**

- 7.1 Sanofi-Aventis
- 7.2 Novartis Pharma ZAO
- 7.3 Roche Moscow Ltd.
- 7.4 Farmstandart OAO
- 7.5 Akrikhin OAO

## List Of Figures

### LIST OF FIGURES:

- Figure 2-1: Population (Million), 2007-2010
- Figure 2-2: Life Expectancy of Male & Female (Years), 2005-2010
- Figure 2-3: Share of Young & Old Age Population in Total Population (2004-2010)
- Figure 2-4: Number of Doctors (per '000 Population), 2005-2010
- Figure 2-5: Share of Healthcare Expenditure in GDP (2007-2010)
- Figure 2-6: Per Head Healthcare Expenditure (US\$), 2007-2010
- Figure 3-1: Pharmaceutical Market (Billion RUB), 2007-2010
- Figure 3-2: Pharmaceutical Market Breakup by Segment (%), 2007-2010
- Figure 3-3: Forecast for Pharmaceutical Market (Billion RUB), 2011-2013
- Figure 3-4: Forecast for Pharmaceutical Market by Segment (%), 2013
- Figure 3-5: Global - Top Pharmaceutical Retail Markets (Billion US\$), 2009
- Figure 3-6: Global - Per Head Drug Consumption in Top Pharmaceutical Markets (US\$), 2009
- Figure 3-7: Share of Rx & OTC Drugs in Out-of-Pocket Expenditure (2009)
- Figure 3-8: Share of Local & Imported Drugs in Out-of-Pocket Expenditure (2009)
- Figure 3-9: Commercial Drugs Market (Billion RUB), 2008-2010
- Figure 3-10: Forecast for Commercial Drugs Market (Billion RUB), 2011-2013
- Figure 3-11: Share of Imported & Domestic Drugs in Commercial Drugs Market by Sales Value (2007-2010)
- Figure 3-12: Share of Imported & Domestic Drugs in Commercial Drugs Market by Sales Volume (2007-2010)
- Figure 3-13: Share of RX & OTC Drugs in Commercial Drugs Market by Sales Value (2007-2010)
- Figure 3-14: Share of RX & OTC Drugs in Commercial Drugs Market by Sales Volume (2007-2010)
- Figure 3-15: Growth of ATC Groups in Commercial Drugs Market (%), 2009
- Figure 3-16: Price Index for Drugs in Commercial Drugs Market (%), 2006-2009
- Figure 3-17: Price Index for Imported & Domestic Drugs in Commercial Drugs Market (%), 2006-2009
- Figure 3-18: Consumer Price Index (%), 2009
- Figure 3-19: State Segment of Pharmaceutical Market (Billion RUB), 2007-2010
- Figure 3-20: Forecast for State Segment of Pharmaceutical Market (Billion RUB), 2011-2013
- Figure 3-21: Disbursement under DLO Program (Billion RUB), 2008-2010
- Figure 3-22: Share of Imported & Domestic Drugs under DLO Program by Sales Value

(2008-2010)

Figure 3-23: Share of Imported & Domestic Drugs under DLO Program by Sales Volume (2008-2010)

Figure 3-24: Share of RX & OTC Drugs under DLO Program by Sales Value (2008-2010)

Figure 3-25: Share of RX & OTC Drugs under DLO Program by Sales Volume (2008-2010)

Figure 3-26: Share of Imported & Domestic Drugs under Hospital Segment by Sales Value (2008-2010)

Figure 3-27: Share of Imported & Domestic Drugs under Hospital Segment by Sales Volume (2008-2010)

Figure 3-28: Parapharmaceutical Market (Billion RUB), 2008-2010

Figure 3-29: Forecast for Parapharmaceutical Market (Billion RUB), 2011-2013

Figure 3-30: Nutritional Supplements Market (Million US\$), 2008-2010

Figure 3-31: Share of Imported & Domestic Nutritional Supplements (2010)

Figure 3-32: Deaths by Circulatory System Diseases (Million), 2002, 2006 & 2010

Figure 3-33: Hepatitis C Market (Million US\$), 2009-2013

Figure 3-34: Number of HIV Patients (Million), 2008-2010

Figure 3-35: Number of Diagnosed Diabetes Patients (Million), 2010 & 2030

Figure 3-36: Insulin Market (Million US\$), 2007-2010

Figure 3-37: Cancer Deaths (Per 100,000), 2002, 2006 & 2010

Figure 4-1: Number of Clinical Trials Approved (2007-2010)

Figure 4-2: Number of Patients Planned to be recruited in Clinical Trials (2008-2010)

Figure 4-3: Clinical Trials by Therapeutic Area (%), 2009

Figure 4-4: Clinical Trials by Sponsor Country (%), 2009

Figure 5-1: Commercial Drug Sales by Price Category (%), 2008 & 2009

Figure 5-2: Personal Disposable Income (Billion US\$), 2009-2013

Figure 5-3: Forecast for Population (Million), 2011-2013

## List Of Tables

### LIST OF TABLES:

Table 3-1: Sales Structure of ATC Groups in Commercial Drugs Market (2009)

Table 3-2: Leading Pharmaceutical Companies in Commercial Drugs Market by Sales (Million RUB), 2009

Table 3-3: Leading Drugs in Commercial Drugs Market by Sales (Million RUB), 2009

Table 3-4: Drugs Sales Structure of ATC Groups under DLO Program (2009)

Table 3-5: Leading Pharmaceutical Companies under DLO Program by Sales (Million RUB), 2009

Table 3-6: Leading Drugs under DLO Program by Sales (Million RUB), 2009

Table 3-7: Sales Structure of ATC Groups in Hospital Segment (2009)

Table 3-8: Leading Pharmaceutical Companies by Sales under Hospital Segment (Million RUB), 2009

Table 3-9: Leading Trade Names under Hospital Segment by Sales (Million RUB), 2009

Table 4-1: Number of Clinical Trials by Top Six Sponsors (2009)

Table 7-1: Sanofi-Aventis - Strengths & Weaknesses

Table 7-2: Novartis Pharma ZAO - Strengths & Weaknesses

Table 7-3: Roche Moscow Ltd. - Strengths & Weaknesses

Table 7-4: Farmstandart OAO - Strengths & Weaknesses

Table 7-5: Akrikhin OAO - Strengths & Weaknesses

## I would like to order

Product name: Russian Pharma Sector Forecast to 2013

Product link: <https://marketpublishers.com/r/RDB40478C51EN.html>

Price: US\$ 800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RDB40478C51EN.html>